The Claim
Liraglutide 3.0 mg reduces the need for basal insulin by an average of 15 units per day at 56 weeks compared to placebo in overweight or obese adults with type 2 diabetes, while achieving similar fasting glucose targets. The liraglutide group required a mean increase of 3 units from baseline, versus 18 units with placebo (p < 0.0001).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Liraglutide 3.0 mg lowers the daily dose of basal insulin needed by 15 units after 56 weeks of treatment in overweight or obese adults with type 2 diabetes, compared to placebo, and keeps blood sugar levels stable.
See the scientific wording
Liraglutide 3.0 mg reduces the need for basal insulin by an average of 15 units per day at 56 weeks compared to placebo in overweight or obese adults with type 2 diabetes, while achieving similar fasting glucose targets. The liraglutide group required a mean increase of only 3 units from baseline, versus 18 units with placebo (p < 0.0001).
Liraglutide acts like a natural hormone that tells the brain and stomach to feel full and slow down food digestion. This makes people eat less and absorb nutrients more slowly, causing weight loss. Weight loss and the direct effects of the hormone lower blood sugar, so the body needs less injected insulin to keep blood sugar levels healthy.
What the research says
1 studyThe study found that people taking liraglutide needed only 3 extra units of insulin per day, while those on placebo needed 18 extra units — a big difference that matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.